Keywords: جهش EGFR; Non-small cell lung cancer; EGFR mutation; Brain metastases; Stereotactic radiosurgery;
مقالات ISI جهش EGFR (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: جهش EGFR; Lung adenocarcinoma; EGFR mutation; Computed tomography;
Keywords: جهش EGFR; Large cell lung carcinoma (LCC); World Health Organization (WHO) 2015 Classification; Clinicopathological characteristics; Survival; Chemotherapy; EGFR mutation;
Keywords: جهش EGFR; Radiotherapy; Stereotactic radiotherapy; Brain irradiation; Targeted therapy; EGFR mutation; ALK translocation;
Keywords: جهش EGFR; Never-smoker small-cell lung cancer; Prognosis; EGFR mutation; Environmental tobacco smoke; Atomic bomb survivor;
Keywords: جهش EGFR; Acquired resistance; EGFR mutation; Gefitinib; Autopsy; Molecular target therapy; T790M mutation;
Keywords: جهش EGFR; Lung adenocarcinoma; Biomarkers; African Caribbean; EGFR mutation;
Keywords: جهش EGFR; Non-small cell lung cancer; EGFR mutation; Afatinib; Acquired resistance; T790M; Progression biopsy;
Keywords: جهش EGFR; Non-small cell lung cancer; Metastasis; EGFR mutation; Uterus;
Keywords: جهش EGFR; Non-small cell lung  cancer; Adenosquamous; EGFR mutation; Histology discordance;
Keywords: جهش EGFR; Brain metastases; Adenocarcinoma; Lung cancer; EGFR mutation; BRAF mutation;
Keywords: جهش EGFR; EGFR mutation; EGFR-TKI therapy; Immunohistochemistry; Lung adenocarcinoma; PD-L1
Keywords: جهش EGFR; EGFR-TKI; epidermal growth factor receptor tyrosine kinase inhibitor; MST; median survival time; HGF; hepatocyte growth factor; FISH; fluorescence in situ hybridization; PTEN; phosphatase and tensin homolog deleted from chromosome 10; PI3K; phosphoinositi
Keywords: جهش EGFR; EGFR-TKI; EGFR mutation; HGF; Acquired resistance; Intrinsic resistance
Keywords: جهش EGFR; EGFR mutation; KRAS mutation; ROS1; Non-small cell lung cancer
Keywords: جهش EGFR; Drug resistance; EGFR mutation; Lung cancer; Alpha shape; Solid angle; Protein surface geometric properties
EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib
Keywords: جهش EGFR; Adenocarcinoma; Dacomitinib; EGFR mutation; Lung cancer; Tyrosine kinase inhibitor;
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors
Keywords: جهش EGFR; Complications; Computed tomography-guided percutaneous core needle biopsy; EGFR mutation; Non-small cell lung cancer; Research biopsies;
A study of therapy targeted EGFR/ALK mutations in Indian patients with lung adenocarcinoma: A clinical and epidemiological study
Keywords: جهش EGFR; Lung adenocarcinoma; Indian; EGFR mutation; ALK fusion oncogene; Targeted therapy;
Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation: A meta-analysis
Keywords: جهش EGFR; Non-small cell lung cancer; EGFR mutation; Brain metastases; Radiotherapy; Tyrosine kinase inhibitor;
Isolated Brain Metastases as the First Relapse After the Curative Surgical Resection in Non-Small-Cell Lung Cancer Patients With an EGFR Mutation
Keywords: جهش EGFR; Brain metastases; EGFR mutation; Isolated; Neurological symptom; Non-small-cell lung cancer; Prognosis; Relapse;
Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR
Keywords: جهش EGFR; Non-small cell lung cancer; EGFR mutation; TKI; HIF-1α; c-Jun;
Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses
Keywords: جهش EGFR; EGFR mutation; cMET amplification; Resistance; Crizotinib;
Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial
Keywords: جهش EGFR; Gefitinib; Non-small cell lung cancer; EGFR mutation;
Next-generation sequencing analysis identifies genomic alterations in pathological morphologies: A case of pulmonary carcinosarcoma harboring EGFR mutations
Keywords: جهش EGFR; Pulmonary carcinosarcoma; EGFR mutation; Next-generation sequencing; Genomic alterations;
Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations
Keywords: جهش EGFR; NSCLC; Non-small cell lung cancer; EGFR; Epidermal growth factor receptor; OS; Overall survival; PD; Progressive disease; PFS; Progression-free survival; Gefitinib; Pemetrexed; EGFR mutation; Beyond progressive disease;
The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer
Keywords: جهش EGFR; Depth of response; EGFR mutation; Tyrosine kinase inhibitor; Chemotherapy;
Added prognostic value of CT characteristics and IASLC/ATS/ERS histologic subtype in surgically resected lung adenocarcinomas
Keywords: جهش EGFR; Lung adenocarcinoma; Prognosis; CT characteristics; Histologic subtype; EGFR mutation;
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer
Keywords: جهش EGFR; NSCLC; AUY922; HSP90 inhibitor; EGFR mutation; KRAS mutation; ALK rearrangement;
Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas
Keywords: جهش EGFR; EGFR mutation; Genetic heterogeneity; Lung adenocarcinoma; Next-generation sequencing; Primary resistance;
Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis
Keywords: جهش EGFR; EGFR mutation; Immunotherapy; Nivolumab; NSCLC; Radiation;
Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion
Keywords: جهش EGFR; Acquired resistance; ctDNA; EGFR mutation; FGFR3 fusion; Non-small-cell lung cancer;
Efficacité de l'erlotinib en réanimation chez les patients présentant un cancer bronchique non à petites cellules avec une mutation de l'EGFR
Keywords: جهش EGFR; Adénocarcinome bronchique; Erlotinib; Réanimation; Mutation EGFR; Bronchial adenocarcinoma; Erlotinib; Critical care; EGFR mutation;
Métastases mammaires des cancers bronchopulmonaires avec mutation de l'EGFR
Keywords: جهش EGFR; Cancer bronchique; Site métastatique atypique; Métastase mammaire; Mutation EGFR; Mutation T790M; Lung cancer; Atypical metastatic site; Breast metastasis; EGFR mutation; T790M mutation;
Original articleEGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology
Keywords: جهش EGFR; Lung cancer; Molecular pathology; EGFR mutation; KRAS Mutation; Fully automated real-time PCR;
The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613
Keywords: جهش EGFR; AZD9291; Blood; EGFR mutation; Gefitinib; Lung;
Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study
Keywords: جهش EGFR; Lung cancer; Adenocarcinoma; EGFR mutation; EGFR TKI retreatment; Exon 21 mutation; Females; Drug holiday; Overall survival; Progression free survival;
Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma
Keywords: جهش EGFR; Lung cancer; EGFR mutation; Prognostic factor;
Correlation between molecular analysis, diagnosis according to the 2015 WHO classification of unresected lung tumours and TTF1 expression in small biopsies and cytology specimens from 344 non-small cell lung carcinoma patients
Keywords: جهش EGFR; Non-small cell lung carcinoma; EGFR mutation; TTF1 immunohistochemistry; 2015 WHO classification;
Brain metastasesTreatment options for patients with brain metastases from EGFR/ALK-driven lung cancer
Keywords: جهش EGFR; Non-small cell lung cancer; Brain metastases; EGFR mutation; ALK translocation; Whole brain radiotherapy; Stereotactic radiotherapy;
ReviewSBRT for oligoprogressive oncogene addicted NSCLC
Keywords: جهش EGFR; Stereotactic body radiotherapy (SBRT); Oligoprogressive disease (OPD); Oncogene addicted lung cancer; Resistance to targeted therapy; Tyrosine kinase inhibitors; EGFR mutation;
Multiplex Ultrasensitive Genotyping of Patients with Non-Small Cell Lung Cancer for Epidermal Growth Factor Receptor (EGFR) Mutations by Means of Picodroplet Digital PCR
Keywords: جهش EGFR; NSCLC; non-small cell lung cancer; TKI; tyrosine kinase inhibitor; PFS; progression-free survival; SARMS; Scorpion Amplification Refractory Mutation System; dPCR; digital polymerase chain reaction; ddPCR; picodroplet dPCR; mCRC; metastatic colorectal ca
Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells
Keywords: جهش EGFR; EGFR mutation; Immunotherapy; Acquired resistance; EGFR-TKIs; Epithelial to mesenchymal transition (EMT); Erlotinib;
Les cancers bronchiques non à petites cellules EGFR-mutés
Keywords: جهش EGFR; Cancer bronchique non à petites cellules; Mutation EGFR; Non-small cell lung cancer; EGFR mutation;
Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer
Keywords: جهش EGFR; Osimertinib; Gefitinib; C797S mutation; EGFR mutation; Non-small cell lung cancer;
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis
Keywords: جهش EGFR; NSCLC; EGFR mutation; Immune checkpoint inhibitors; Predictive biomarker;
Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation
Keywords: جهش EGFR; PD-L1; EGFR mutation; Acquired resistance; Gefitinib; Autopsy; Immune biomarkers;
EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib
Keywords: جهش EGFR; NSCLC; EGFR mutation; Afatinib; Targeted therapy;
Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench
Keywords: جهش EGFR; EGFR mutation; Acquired resistance; Molecular mechanisms; Drug-tolerant state; Microenvironment; Tumor heterogeneity;
Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers
Keywords: جهش EGFR; Non-small cell lung cancer; EGFR mutation; Tyrosine kinase inhibitors; cost-effectiveness;